Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Inclusion criteria

• Patients who are recipients of a renal transplant.
• Patients treated with an immunosuppressive regiment including MMF before recruitment.
• Patients suffering from GI side effects related to MMF standard doses or patients treated with a reduced MMF dose to control the aforementioned GI side effects.
• Patients 18 years or older.
• Patients who have given written informed consent to participate in the study
• Patients complying with all study requirements including completing questionnaires and attending to the three study visits.

Exclusion criteria

• Patients with GI symptoms assumed or known not to be caused by MPA therapy (eg. oral bisphosphonate induced, infectious diarrhea)
• Acute rejection less than 1 week before recruitment.
• Females of childbearing potential who are pregnant, planning to get pregnant and/or breast feeding or not willing to practice an approved method of birth control.
• Presence of psychiatric disorder, such as schizophrenia or major depression, in the investigator's opinion, could interfere with study requirements.
• Patients undergoing surgery due to acute illness or hospitalized.
• Existence of any medical condition which, in the investigator's opinion based on anamnesis or medical records, could affect study completion, including but not limiting visual problems or cognitive deterioration.
• Patients currently treated or who have been treated with any other study drug or treatment within 30 days prior to baseline visit.

Other protocol-defined inclusion/exclusion criteria may apply.